Multiple unspecified cancer-related pathways

Multiple unspecified cancer-related pathways is a collective term used to describe a diverse set of signaling cascades and biological processes that contribute to the initiation, progression, and metastasis of various cancers. This designation does not refer to a single, discrete molecular target such as a specific protein, receptor, or enzyme, but rather to the complex network of interactions that govern cellular behavior (National Cancer Institute, 2023). Common pathways often associated with this broad category include the PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and Wnt/beta-catenin signaling routes, which regulate cell growth, survival, and differentiation (Hanahan & Weinberg, 2011). Because this term is non-specific, it is often used in early-stage research or when a therapeutic agent demonstrates broad-spectrum activity across multiple oncogenic mechanisms. Targeting these pathways typically involves the use of multi-target inhibitors or combination therapies designed to overcome redundant signaling and drug resistance (NIH, 2022). From a drug discovery perspective, this entry is considered incorrect as a target because it lacks the molecular specificity required for precise pharmacological characterization. Consequently, it serves more as a functional category for drugs that affect the tumor microenvironment or multiple intracellular signals simultaneously.

Not applicable as this is a broad grouping of various biological pathways rather than a single molecular target.